RESUMO
Autism spectrum disorder (ASD) is complex neurobehavioral condition influenced by several cellular and molecular mechanisms that are often concerned with synaptogenesis and synaptic activity. Based on the excitation/inhibition (E/I) imbalance theory, ASD could be the result of disruption in excitatory and inhibitory synaptic transmission across the brain. The prefrontal cortex (PFC) is the chief regulator of executive function and can be affected by altered neuronal excitation and inhibition in the course of ASD. The molecular mechanisms involved in E/I imbalance are subject to epigenetic regulation. In ASD, altered enrichment and spreading of histone H3 and H4 modifications such as the activation-linked H3K4me2/3, H3K9ac, and H3K27ac, and repression-linked H3K9me2, H3K27me3, and H4K20me2 in the PFC result in dysregulation of molecules mediating synaptic excitation (ARC, EGR1, mGluR2, mGluR3, GluN2A, and GluN2B) and synaptic inhibition (BSN, EphA7, SLC6A1). Histone modifications are a dynamic component of the epigenetic regulatory elements with a pronounced effect on patterns of gene expression with regards to any biological process. The excitation/inhibition imbalance associated with ASD is based on the excitatory and inhibitory synaptic activity in different regions of the brain, including the PFC, the ultimate outcome of which is highly influenced by transcriptional activity of relevant genes.
RESUMO
A new multifunctional graphene oxide/Cu (II)-porphyrin MOF nanocomposite (CuG) comprised of Cu-TCPP MOF supported on graphene oxide (GO) nanosheets, has been fabricated by a solvothermal method at low temperature and one-pot process. Cu-TCPP MOF with universal advantages, such as high porosity, nontoxicity, large surface area, and safe biodegradation, combined with GO allows the achievement of an efficient doxorubicin loading (45.7%) and smart pH-responsive release for chemotherapy. More significantly, more than 97% of DOX was released by CuG at pH 5 which was more than that at pH 7.4 (~ 33.5%), while Cu-TCPP MOF displayed DOX release of 68.5% and 49% at pH 5 and 7.4, respectively, illustrating the effect of GO on the smart MOF construction for controllable releasing behavior in vitro. The results of in vitro anticancer experiments demonstrate that the developed nanocarrier exhibited slight or no cytotoxicity on normal cells, while the drug-loaded nanocarrier increased significant cancer cell-killing ability with higher therapeutic efficacy than free DOX, indicating the sustained release behavior of the CuG nanocarrier without any "burst effect". Moreover, the in vivo experiments demonstrated that the CuG-DOX exhibited significantly higher anticancer efficiency compared with free DOX. High anti-cancer therapeutic efficacy of this nanoscale carrier as an efficient pH sensitive agent, has the potential to enter further biomedical investigations. A new smart multifunctional graphene oxide-Cu (II)-porphyrin MOF nanocomposite (CuG) formed of Cu-TCPP MOF and graphene oxide (GO) has successfully fabricated and demonstrated an efficient pH-responsive drug release behavior in cancer therapy without using any targeting ligand.
Assuntos
Antineoplásicos/administração & dosagem , Cobre/química , Portadores de Fármacos/síntese química , Grafite/química , Porfirinas/química , Animais , Antineoplásicos/química , Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Doxorrubicina/química , Doxorrubicina/uso terapêutico , Sistemas de Liberação de Medicamentos , Desenho de Fármacos , Liberação Controlada de Fármacos , Feminino , Humanos , Concentração de Íons de Hidrogênio , Células MCF-7 , Estruturas Metalorgânicas/química , Camundongos , Camundongos Endogâmicos BALB C , Modelos Moleculares , Estrutura Molecular , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
Cu-BTC framework has received a considerable attention in recent years as a drug carrier candidate for cancer treatment due to its unique structural properties and promising biocompatibility. However, its intrinsic deficiency for medical imaging potentially limits its bioapplications; To address this subject, a magnetic nano/microscale MOF has been successfully fabricated by introducing Fe3O4 nanoparticles as an imaging agent into the porous isoreticular MOF [Cu3(BTC)2] as a drug carrier. The synthesized magnetic MOFs exhibits a high loading capacity (40.5%) toward the model anticancer DOX with an excellent pH-responsive drug release. The proposed nanocomposite not only possesses large surface area, high magnetic response, large mesopore volume, high transverse relaxivity (r 2) and good stability but also exhibits superior biocompatibility, specific tumor cellular uptake, and significant cancer cell viability inhibitory effect without any targeting agent. It is expected that the synthesized magnetic nano/microcomposite may be used for clinical purposes and can also serve as a platform for photoactive antibacterial therapy ae well as pH/GSH/photo-triple-responsive nanocarrier.